Search
Young researchers to benefit from EHA training and mentoring
Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreImproved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read moreThe Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Read moreGenome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.
Read moreEvaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.
The International Society on Thrombosis and Haemostasis (ISTH) Hosts its Second Advanced Training Course on Thrombosis and Haemostasis on March 13-16, 2014
The Second Advance Training Course is a follow-up to the successful inaugural course organized in 2011 and attended by 200 professionals. Course speakers include nine international and regional experts in the field of thrombosis and haemostasis.
Read moreReport on first EHA-SWG Scientific Meeting
The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.
Read morePersonalized medicine promises radical improvements to healthcare in Europe
And the precision that personalised medicine will bring good prospects for better use of resources.
Read more